1wbt: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
<StructureSection load='1wbt' size='340' side='right' caption='[[1wbt]], [[Resolution|resolution]] 2.00Å' scene=''> | <StructureSection load='1wbt' size='340' side='right' caption='[[1wbt]], [[Resolution|resolution]] 2.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1wbt]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[1wbt]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1WBT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1WBT FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=WBT:3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE'>WBT</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=WBT:3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE'>WBT</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1a9u|1a9u]], [[1bl6|1bl6]], [[1bl7|1bl7]], [[1bmk|1bmk]], [[1di9|1di9]], [[1ian|1ian]], [[1kv1|1kv1]], [[1kv2|1kv2]], [[1m7q|1m7q]], [[1ouk|1ouk]], [[1ouy|1ouy]], [[1ove|1ove]], [[1oz1|1oz1]], [[1r39|1r39]], [[1r3c|1r3c]], [[1w7h|1w7h]], [[1w82|1w82]], [[1w83|1w83]], [[1w84|1w84]], [[1wbn|1wbn]], [[1wbo|1wbo]], [[1wbs|1wbs]], [[1wbv|1wbv]], [[1wbw|1wbw]], [[1wfc|1wfc]], [[1yqj|1yqj]], [[1zz2|1zz2]], [[1zzl|1zzl]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1a9u|1a9u]], [[1bl6|1bl6]], [[1bl7|1bl7]], [[1bmk|1bmk]], [[1di9|1di9]], [[1ian|1ian]], [[1kv1|1kv1]], [[1kv2|1kv2]], [[1m7q|1m7q]], [[1ouk|1ouk]], [[1ouy|1ouy]], [[1ove|1ove]], [[1oz1|1oz1]], [[1r39|1r39]], [[1r3c|1r3c]], [[1w7h|1w7h]], [[1w82|1w82]], [[1w83|1w83]], [[1w84|1w84]], [[1wbn|1wbn]], [[1wbo|1wbo]], [[1wbs|1wbs]], [[1wbv|1wbv]], [[1wbw|1wbw]], [[1wfc|1wfc]], [[1yqj|1yqj]], [[1zz2|1zz2]], [[1zzl|1zzl]]</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1, 2.7.11.8, 2.7.11.9, 2.7.11.10, 2.7.11.11, 2.7.11.12, 2.7.11.13, 2.7.11.21, 2.7.11.22, 2.7.11.24, 2.7.11.25, 2.7.11.30 and 2.7.12.1 2.7.11.1, 2.7.11.8, 2.7.11.9, 2.7.11.10, 2.7.11.11, 2.7.11.12, 2.7.11.13, 2.7.11.21, 2.7.11.22, 2.7.11.24, 2.7.11.25, 2.7.11.30 and 2.7.12.1] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1wbt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1wbt OCA], [http://www.rcsb.org/pdb/explore.do?structureId=1wbt RCSB], [http://www.ebi.ac.uk/pdbsum/1wbt PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1wbt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1wbt OCA], [http://pdbe.org/1wbt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1wbt RCSB], [http://www.ebi.ac.uk/pdbsum/1wbt PDBsum]</span></td></tr> | ||
</table> | </table> | ||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
| Line 26: | Line 26: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 1wbt" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
| Line 33: | Line 34: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Human]] | ||
[[Category: | [[Category: Transferase]] | ||
[[Category: Cleasby, A]] | [[Category: Cleasby, A]] | ||
[[Category: Devine, L A]] | [[Category: Devine, L A]] | ||
| Line 45: | Line 46: | ||
[[Category: Phosphorylation]] | [[Category: Phosphorylation]] | ||
[[Category: Serine/threonine-protein kinase]] | [[Category: Serine/threonine-protein kinase]] | ||
Revision as of 01:00, 12 September 2015
IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
Structural highlights
Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedWe describe the structure-guided optimization of the molecular fragments 2-amino-3-benzyloxypyridine 1 (IC(50) 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC(50) 35 microM) identified using X-ray crystallographic screening of p38alpha MAP kinase. Using two separate case studies, the article focuses on the key compounds synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate significant increases in activity. We describe the process of compound elaboration either through the growing out from fragments into adjacent pockets or through the conjoining of overlapping fragments and demonstrate that we have exploited the mobile conserved activation loop, consisting in part of Asp168-Phe169-Gly170 (DFG), to generate significant improvements in potency and kinase selectivity. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.,Gill AL, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, Walker MT, Congreve MS, Devine LA, Tisi D, O'Reilly M, Seavers LC, Davis DJ, Curry J, Anthony R, Padova A, Murray CW, Carr RA, Jhoti H J Med Chem. 2005 Jan 27;48(2):414-26. PMID:15658855[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||||